Production (Stage)
Tarsus Pharmaceuticals, Inc.
TARS
$42.98
$0.010.02%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 29.70% | 44.84% | 40.18% | -5.94% | -52.57% |
| Total Depreciation and Amortization | 70.37% | 24.50% | 16.39% | 31.32% | 159.62% |
| Total Amortization of Deferred Charges | 21.93% | 24.32% | 27.72% | 9.78% | 40.74% |
| Total Other Non-Cash Items | -5.97% | 23.84% | 28.02% | 97.05% | 130.14% |
| Change in Net Operating Assets | 77.76% | -104.03% | 462.85% | 229.12% | -510.45% |
| Cash from Operations | 45.35% | 43.61% | 73.26% | 39.55% | -72.00% |
| Capital Expenditure | -239.08% | -- | 24.80% | -32.02% | 48.82% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 66.34% | -433.34% | -92.86% | -160.86% | -977.17% |
| Cash from Investing | 65.82% | -433.75% | -93.40% | -163.23% | -1,005.12% |
| Total Debt Issued | -- | -- | -100.00% | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 37.38% | -85.19% | -99.32% | -- | 764,561.54% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 25.55% | -85.19% | -99.39% | 8,197.84% | 2,069.78% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 359.17% | -4,469.80% | -104.07% | -130.93% | -451.69% |